ARDEA - Entering the Pivotal Phase
After a long wait, Ardea (RDEA) reached an agreement with the FDA on the proposed PhIII development plans for Lesinurad (RDEA594, Urate Transporter regulator, Gout, PhIII) and expects to initiate the trials by 4Q11. There is a major unmet medical need for a better treatment option for the majority of gout pts. How will Lesinurad target the WW gout market? Management plans on the development/partnering etc. of Lesinurad is discussed in the report released on 12th September, 2011 on RDEA titled “Entering the Pivotal Phase”. For more details please ask for our initiation report on Ardea.
COMPANIES MENTIONED
ARDEA
ARDEA
